Queensland Health Immunisation Program Queensland Paediatric RSV Prevention Program Product Selection Guide



| Australian Immunisation Handbook – RSV Chapter | Queensland Paediatric RSV Prevention Program webpage | Abrysvo | Nirsevimab (Beyfortus) | Arexvy |
|---|---|--|--|-----------------------------------|
| | | A CONTRACTOR OF A MERCING CONTRACTOR OF A MER | 50mg 100mg Image: State of the state o | Adjuvanted RSV Vaccine |
| Pregnancy | Between 28 to 36 weeks gestation* *Can be given after 36 weeks if missed, refer to Australian Immunisation Handbook for more information | Recommended and funded under the National Immunisation Program | Not registered for use | Not registered for use |
| Infants | Birth to less than 24 months* *Refer to eligibility criteria prior to administration via the Queensland Paediatric RSV Prevention webpage | Not registered for use | Recommended and funded under the Queensland Paediatric RSV Prevention Program | Not registered for use |
| Adults 50 years and above | 50 years and above with increased risk of RSV disease *Refer to the Australian Immunisation Handbook for more information | Not registered for use | Not registered for use | Registered* but NOT funded |
| T 7 1 | All adults 60 years and above *Refer to the Australian Immunisation Handbook for more information | Registered* but NOT funded | Not registered for use | Registered* but NOT funded |

ProductSelectionGuide_V1.0_20250702